bet365 api
Townsville Don't miss out on the headlines from Townsville. Followed categories will be added to My News. The month of May began with headlines focused on then Townsville Mayor Troy Thompson and ended with him as he continued to cling to his job despite widespread disdain for the alleged lies about his background during local-government elections. Despite the stain on Townsville’s reputation, a tenacious Thompson’s tenuous grasp on power held by the end of the month, even after then Premiere Steven Miles and the 10 sitting councillors called on him to do the right thing and resign following a calamitous media interview. While the Thompson train wreck provided an unwelcome political sideshow, a number of other pressing issues also made headlines. May 2 Townsville DV Toll at Crisis Point Police on the front-line of Townsville’s domestic violence crisis are facing unprecedented challenges , responding to as many as 50 call-outs a day and they anticipate these numbers will only surge. The Townsville Domestic, Family Violence and Vulnerable Persons Unit say police respond to between 35-50 DV-related call outs every day and anticipate those numbers to rise. Senior Sergeant Adam Golding, Sergeant Elise Feltham and Townsville District Officer Acting Chief Superintendent Tom Armitt, launch Domestic and Family Violence Prevention Month. Picture: Shae Beplate. Third time unlucky ... again Mayor Troy Thompson attempted three motions to gain up to three political advisers, which were denied each time because not enough councillors supported the decision. Councillors also identified their preferred option to act as a chief executive officer known as ‘Candidate Z’ after almost two hours in confidential business. May 3 Thugs steal car from wheelchair-bound mum A woman left wheelchair-bound after being struck by a stolen car has been dealt another devastating blow after her modified vehicle was recently stolen by shameless thieves who openly mocked her . Light in the darkness A young Townsville advocate has opened up about her own experiences with sexual assault as she uses her platform to boost awareness and support for survivors to create discussion on how Australians can create safer spaces. Evie Clayton is an advocate for sexual assault and domestic and family violence survivors. Picture: Shae Beplate. May 4 Bonza demise plane awful North-West Queensland community leaders have been left gutted by the collapse of Bonza airline, with residents now forced to fork out up to 10 times more for flights to see family, friends and for specialist medical appointments. May 8 Green light for mine A $300m phosphate mine in the North West has received a green light, with 445 jobs created as part of the project. The state government has granted mining leases to the Paradise South phosphate mine, about 130km northwest of Mount Isa near the Lady Loretta zinc mine, with plans in place for company North West Phosphate to use local services as part of the project. The Burdekin Rum team at ARDO Rooftop: Kelly Shimota, Tim Lamb, Raelene Bates, Warren Tink, Adrian Hogan, Jason Chan, Olivia McCormick, Prue Yeung, Vicki Johnson and Anthony and Sophie Duggan. Picture: Doug Simpson Media NQ distillery in spirited win A North Queensland distillery is continuing to collect accolades for its range of rums. Burdekin Rum’s Premium Aged Rum has won Best of Category for its bottled and blended pot Still Rum and Best of Class f or its bottled and blended Cane Spirit at the American Distilling Institute International Spirits Competition 2024. May 11 Danger to our kids Social media has been labelled a public health risk with children and young people exposed to damaging images and content they don’t have the developmental maturity to cope with. Acting Chief Health Officer Associate Professor Catherine McDougall told the Townsville Bulletin’s Future Townsville event that social media access for children was causing distress for young people, with it leading to a rise in hospital admissions. Insulted MPs in fight for Bruce North Queensland MPs are “insulted and infuriated” after the Labor government promised $467m for Bruce Highway works in marginal electorates, with one saying a “big picture plan” is needed. LNP MPs Phillip Thompson and Andrew Willcox have come out swinging after the pre-budget announcement, which will fund works in the Far North and South East. May 14 Department of Environment, Science and Innovation Wildlife Officers remove a saltwater crocodile, also known as an estuarine crocodile, measuring at least four metres in length at Port Hinchinbrook in Cardwell. Picture: Cameron Bates Rogue croc caught at Port Hinchinbrook A monster saltwater crocodile believed to be responsible for an attack on a human and death of at least one pet dog has been captured in spectacular fashion at a North Queensland marina. The saltie, also known as an estuarine crocodile, measuring at least four metres in length was caught in a large metal trap placed by the Department of Environment, Science and Innovation at Port Hinchinbrook in Cardwell Waterfront, housing top budget list An upgraded waterfront with the Great Barrier Reef education precinct, a fair chunk of Bruce Highway funding, housing investment and workforce shortage assistance are leading the ticket of North Queensland budget priorities as the nation is poised to hear what projects will get the green light or further funding. Townsville Enterprise has released its priorities for the budget , which includes $100m worth of investment into the GBR education precinct, which would include a new aquarium. May 15 Townsville Bulletin front page, May 15, 2024. Picture: Supplied We deserve better North Queensland’s leaders have come out swinging after last night’s Federal Budget ‘snubbed’ the region, including t he absence of any mone y to rebuild Townsville’s Reef HQ aquarium. Crime far from kid’s play A young Mackay family who moved to Townsville to seek medical treatment for their darling baby girl has received a harrowing introduction to the scourge of local youth crime. Ashleigh Connell, a married mum with 21⁄2-year-old twins Noah and Gracie, said she was prepping breakfast when she noticed “an internal door to the garage was open”. “As I walked outside and notice the side gate open I peered around the corner and my heart fell to the floor,” she said. “My driveway was empty and my new car was gone.” May 16 Robert Malayta, 18, drowned in the Ross River trying to flee police. Teen’s haunting last words as he vanished “Big bro, help” were the last words spoken by a First Nations teenager before he perished in a treacherous river while fleeing from police after reluctantly going for a joy-ride in a stolen car, a pre-inquest into his death has heard . The body of Robert “Robbie” Malayta, 18, was discovered a day later on February 25, 2022, in the Ross River at the Riverway Precinct in Kirwan, Townsville. May 21 Member for Hill Shane Knuth, Member for Hinchinbrook Nick Dametto, Federal Member for Kennedy Bob Katter and KAP Mundingurra candidate Michael Pugh at the Townsville Entertainment Centre. Picture: Evan Morgan MP demands answers as crime cripples As serious youth crime continues to plague Townsville, Hinchinbrook MP Nick Dametto has demanded the Miles Government to provide an urgent update on the progress of its intensive on-country program. Dametto’s call for action comes in the wake of a Townsville boy facing nearly 50 charges related to a series of alleged vehicle, property, and violence offences committed during a three-week rampage. He says it’s already been two months since expressions of interest for the program wrapped up but the public are still waiting for answers. May 23 State’s hotspot of crime Townsville has become the epicentre in the Queensland Police Service’s battle against youth crime, with Taskforce Guardian working overtime to clean up the city’s streets. Since its inception 12 months ago, Taskforce Guardian has launched 13 deployments across the city, surpassing all other police districts across the state . Their efforts within Townsville’s district have resulted in 286 arrests, 871 charges and 129 diversions away from the court system into anti-crime programs. Embattled Townsville mayor Troy Thompson seated next to Councillor Brodie Phillips. Picture: Evan Morgan Mayor not in the SAS Townsville’s mayor has produced his military service number to “put an end” to speculation , however the full contents of his record reveal he did not spend five years in the army or the SAS as he told voters. May 27 Dogs of war Soldiers from across the globe have descended on North Queensland for this year’s Brolga Run Exercise. Troops from Japan, PNG and the US are mucking in together with the locals in pursuit of perfection, but no bond is stronger than the one between our sappers and their canine companions . Australian Army soldier Sapper Flynn Skerke-Irwin and Explosive Detection Dog Ethan from 3rd Combat Engineer Regiment during Exercise Brolga Run 2024 in Townsville Field Training Area, Queensland. May 30 Twist in murder case A Townsville massage parlour owner allegedly killed his wife’s lover in a frenzied stabbing attack when he found out about their affair. Lar Sue, 31, has been charged with murder after allegedly stabbing his wife’s lover above a Thai restaurant on Monday. Sue allegedly confronted his wife and the other man in a Kirwan unit and stabbed him multiple times. May 31 Townsville Bulletin front page, May 31, 2024. Picture: Supplied What a crock Townsville’s embattled mayor is facing fresh allegations of deception, conceding he misled voters about his education, business nous and military career and blaming “100 plus” concussions for his poor memory. Troy Thompson has also apologised to veterans for embellishing his military service in an explosive national television interview in which he disputed lying about his career, saying he “firmly believed” he had given the right information. More Coverage Powders, bars, and banjoes: Our biggest February headlines Cyclones, crime and controversy: Our biggest January headlines Originally published as Townsville Bulletin newspaper headlines for month of May, 2024 Join the conversation Add your comment to this story To join the conversation, please log in. Don't have an account? Register Join the conversation, you are commenting as Logout More related stories News Get job ready: Business offers 17 free training opportunities Staying true to a promise to his grandmother, a Townsville businessman is offering free training to 17 school leavers, unemployed, or under-employed people. Find out more. Read more Townsville ‘We’re always here, always ready’: Christmas Day on the job Essential workers across Townsville spent Christmas Day at work, but they still had plenty of festive spirit. Read about their Christmas. Read more
Kaylene Smikle scored 16 points and made a couple of key baskets down the stretch to help the No. 10 Maryland women’s basketball team hold off George Mason, 66-56, in a matchup of unbeatens Saturday afternoon at the Navy Classic in Annapolis. Maryland (7-0) led by as many as 15 points in the second quarter, but George Mason (6-1) rallied and took the lead late in the third. The Terrapins led by two with just more than three minutes to play when Smikle stole the ball and made a layup while being fouled. The free throw pushed the lead to 58-53, and a putback by Smikle put Maryland up by seven.OSU police probing use of pepper spray in melee
Trump discussed border, trade with Canada's Trudeau after pledging steep tariffsClimate crisis: A plan B needed for wild weather
Continuity Recipe for national success is simple yet powerful: good leaders and long tenures No zero-sum political theatrics, please. No idle shipping containers blocking roads, disrupting lives, and choking the economy, please. Absolutely no disruptive dharnas that paralyse cities. What Pakistanis desperately need are three things: stability, predictability and, above all, continuity of policies. Continuity of policies will provide Pakistan with three critical benefits: attracting investment, fostering sustainable growth, and securing a brighter future for its citizens. Zero-sum political agendas should never be allowed at the expense of national progress. Good leaders – whether uniformed or not – unite people. Bad leaders divide them. Good leaders harness shared values and meaningful connections to foster unity. Bad leaders exploit societal divisions. Bad leaders sow discord. Good leaders – whether uniformed or not – uplift society by healing its wounds; bad leaders exacerbate them. Park Chung-hee, a South Korean politician and former general, served as the country’s third president for 17 years. While his authoritarian rule remains controversial, it was marked by a remarkable continuity of policies that spurred rapid industrialisation and economic growth. Under his leadership, South Korea’s GDP per capita soared from $87 in 1962 to $1,481 in 1980 – an extraordinary 18-fold increase. Lee Teng-hui served as Taiwan’s president for a transformative 12-year period. Lee Teng-hui provided Taiwan with continuity of leadership and continuity of policies. He steered the island's economy away from labour-intensive industries and towards a technologically advanced, high-value manufacturing model. Under his leadership, Taiwan experienced remarkable economic growth, with GDP per capita surging from a modest $6,300 in 1988 to a substantial $15,000 by 2000. Deng Xiaoping's 11-year tenure as China's paramount leader was marked by the 'Reform and Opening Up' policy. Deng, a former military leader, introduced market-oriented economic reforms and opened China to foreign investment. Deng prioritised political stability and social harmony, recognising their importance for economic development. As a result of these reforms, China's GDP per capita soared from $156 in 1978 to $1,400 in just 11 years. Sukarno, a former military officer, led Indonesia for 22 years. While his economic policies were often inconsistent and hindered by political instability, he played a crucial role in laying the foundation for Indonesia's industrialisation and modernisation. Sukarno's ambitious development plans, such as the construction of large-scale infrastructure projects, aimed to modernise the country and improve the lives of its people. Lee Kuan Yew served as Singapore's prime minister for 31 years. Lee had a strong grasp of discipline and strategy. Lee transformed Singapore from a small, impoverished British colony into a global financial hub with one of the highest standards of living in the world. Conclusion: The recipe for national success is simple yet powerful: good leaders and long tenures. Good leaders unite, inspire, and implement forward-looking policies, while long tenures ensure the continuity needed to see those policies bear fruit. Together, they provide the stability and vision essential for lasting progress. In an era of rapid global change, the ability to maintain political stability and economic growth is more crucial than ever. Pakistan, with its immense potential, can realise its destiny if it embraces this simple yet powerful principle: good leaders and long tenures. The writer is a columnist based in Islamabad. He tweets/posts @saleemfarrukh and can be reached at: farrukh15@hotmail.comEx-defense secy: Too early to say Hegseth nomination is dead
Aadi Enters into Exclusive License for Three-Asset ADC Portfolio Developed through a Collaboration between WuXi Biologics and HANGZHOU DAC Aadi Enters Agreement to Sell FYARRO ® and Associated Infrastructure to KAKEN Pharmaceutical for $100M ; Announces PIPE Financing of $100M Cumulative Capital Expected to Fund Operations into Late 2028, Including Anticipated Clinical Data for the ADC Portfolio Co-Founder and Former CEO of ProfoundBio, Baiteng Zhao, Appointed to Aadi Board of Directors Aadi to Hold Webcast and Conference Call on December 20 at 8:00 AM EST LOS ANGELES , Dec. 19, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) today announced it has entered into an exclusive license agreement for development and global commercialization of a three-asset portfolio of preclinical, next-wave antibody-drug conjugates (ADCs), in collaboration with WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), and HANGZHOU DAC BIOTECHNOLOGY CO., LTD. ( HANGZHOU DAC), a global leader in ADC innovation. Per the terms of the license agreement, Aadi is granted exclusive rights to certain patents and know-how pertaining to three preclinical ADC programs leveraging HANGZHOU DAC's CPT113 linker payload technology targeting each of Protein Tyrosine Kinase 7 (PTK7), Mucin-16 (MUC16) and Seizure Related 6 Homolog (SEZ6). Aadi will pay aggregate upfront payments of $44 million for in-licensing such ADC programs. Additionally, Aadi is obligated to pay cumulative development milestone payments of up to $265 million , cumulative commercial milestone payments of up to $540 million and single-digit royalties of sales. To support this transaction, Aadi entered into a subscription agreement with certain qualified institutional buyers and accredited investors for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $100 million , before deducting placement agent fees and other offering expenses. The Company is selling an aggregate of 21,592,000 shares of its common stock ("Common Stock") at a price of $2.40 per share, representing a premium of approximately 3.4% to the closing price on December 19, 2024 on Nasdaq, and pre-funded warrants ("Pre-Funded Warrants") to purchase up to an aggregate of 20,076,500 shares of Common Stock at a purchase price of $2.3999 per Pre-Funded Warrant share. The syndicate was led by Ally Bridge Group, with participation from new investors OrbiMed, Invus, Kalehua Capital and other accredited investors, Tae Han co-founder of ProfoundBio, as well as existing investors, including Avoro Capital, KVP Capital and Acuta Capital Partners. The PIPE financing is expected to close in the first half of 2025, subject to stockholder vote and satisfaction of customary closing conditions. "I'm thrilled to announce our partnership with WuXi Biologics and HANGZHOU DAC to bring forward this thoughtfully selected ADC portfolio. We were deliberate in identifying broadly expressed tumor targets where first-generation ADCs have already shown proof of concept. With our next wave ADC portfolio, we aim to build upon these earlier therapies to deliver improved outcomes for people living with cancer," said David Lennon , PhD, President and CEO of Aadi Bioscience. "The financing underscores the confidence our investors have in both the potential of this portfolio and the strength of Aadi's management team." About the ADC Portfolio Each of the three ADC assets utilizes HANGZHOU DAC's CPT113 ADC platform, which consists of a highly stable yet cleavable linker that delivers a Topoisomerase I (TOPO1) inhibitor payload. The CPT113 platform's linker stability and novel payload has the potential to be highly competitive among the next generation ADC platforms. To effectively leverage the CPT113 platform, Aadi selected tumor targets that are upregulated in high-potential cancer indications and where clinical efficacy has been demonstrated by first-generation ADCs. These assets were discovered through the collaborative efforts of WuXi Biologics and HANGZHOU DAC, utilizing the innovative antibody discovery platform provided by WuXi Biologics and advanced linker-payload technology provided by HANGZHOU DAC. "Leveraging our advanced antibody discovery service, we're glad to enable Aadi to accelerate the discovery of precision therapies targeting some of the most challenging cancers," said Dr. Chris Chen , CEO of WuXi Biologics. "This collaboration underscores our wide recognition as an industry leader in discovery service solutions, and further validates our ability to provide integrated discovery technology platforms for global partners to develop next-generation modalities. We look forward to partnering with Aadi and HANGZHOU DAC to expeditiously move these assets forward into clinical development and benefit patients worldwide." " HANGZHOU DAC's CPT-ADC platform is designed to enable next wave ADC capabilities that surpass first-generation technologies, including two programs already in clinical development in China ," said Dr. Robert Y. Zhao , President and CEO of HANGZHOU DAC Biotechnology. "As a global leader in ADC innovation, we are excited to partner with Aadi and WuXi Biologics to deliver this promising portfolio to patients." Aadi to Sell FYARRO for $100 Million , Cumulative Capital Expected to Fund Operations into Late 2028 In a separate agreement, KAKEN Pharmaceutical Co., Ltd., an R&D driven pharmaceutical company in Japan , has entered into a stock purchase agreement under which KAKEN will acquire Aadi Subsidiary, Inc. and all of its assets, including FYARRO ® (sirolimus protein-bound particles for injectable suspension) (albumin-bound) and associated infrastructure, including the majority of Aadi employees who support the FYARRO ® business. FYARRO is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa), with cumulative revenue of $25.2 million reported over the prior four quarters ended September 30, 2024 . Per the terms of the agreement, Kaken will pay Aadi $100 million in cash at closing, subject to certain adjustments. The transaction is expected to close in the first half of 2025, subject to Aadi stockholder approval and certain closing conditions. Upon the closing of this transaction, KAKEN will also acquire the rights to the Aadi name and trademark. "We are enormously proud of the impact FYARRO has had for people with PEComa, and Kaken's capabilities, coupled with the proven track record of the Aadi team, ensures physicians and patients will continue to have access to this critical treatment," said Lennon. The net proceeds from the PIPE financing and the sale of FYARRO, together with the Company's existing cash, cash equivalents and marketable securities are expected to fund operations into late-2028, including anticipated clinical data readouts for the ADC portfolio. Baiteng Zhao Appointed to the Board of Directors, Brings Significant ADC Expertise Baiteng Zhao, PhD, joins Aadi's board of directors. Zhao co-founded ProfoundBio, a clinical stage next-gen ADC developer, in 2018 and served as the Chairman and CEO of the company until it was acquired by Genmab for $1.8 billion in May 2024 . Prior to ProfoundBio, Dr. Zhao worked at Seagen (now part of Pfizer) for more than eight years and was responsible for the modeling and simulation strategies for the development pipeline and supported preclinical and clinical development of ADC drug candidates. "We are delighted to welcome Baiteng to our Board. His deep expertise and successful track record in ADC development will be instrumental as we tenaciously move this exciting portfolio forward," said Caley Castelein , MD, Chair of the Board of Directors of Aadi Bioscience. "I am thrilled to join the Board at this pivotal moment for Aadi," said Baiteng Zhao, PhD, Board of Directors of Aadi Bioscience and co-founder of ProfoundBio. "PTK7, MUC16 and SEZ6 represent highly promising targets that are commonly overexpressed in cancers with significant unmet therapeutic needs. Coupled with an advanced linker-payload platform that has the potential to enable next-gen ADCs, I believe Aadi is uniquely positioned to make a meaningful impact on patient outcomes. I look forward to collaborating with the leadership team and fellow Board directors to advance these innovative programs and drive transformative progress for patients." Advisors Leerink Partners is serving as financial advisor to Aadi on the sale of FYARRO and the licensing of the ADC portfolio. Jefferies LLC is acting as exclusive placement agent for the PIPE financing. Wilson Sonsini Goodrich & Rosati, P.C. is serving as legal counsel to Aadi. McDermott Will & Emery LLP is serving as legal counsel to Kaken. Cooley LLP is serving as legal counsel to Jefferies LLC. Nomura Securities Co., Ltd. is serving as financial advisor to KAKEN. Conference Call Information The Aadi management team is hosting a conference call and webcast tomorrow, Friday, December 20 th at 8:00 AM EST ( 5:00 AM PST ) to discuss these updates. Participants may access a live webcast of the call and the associated slide presentation on these data through the "Investors & News" page of the Aadi Bioscience website at aadibio.com . To participate via telephone, please register in advance at this link . Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the Company's website for at least 30 days. Additional Information for Stockholders This communication relates to the proposed sale of FYARRO and the proposed PIPE financing and may be deemed to be solicitation material in respect of such transactions. In connection with these proposed transactions, Aadi will file a Proxy Statement with the SEC. This communication is not a substitute for the Proxy Statement or any other documents that Aadi may file with the SEC or send to Aadi stockholders in connection with the proposed transactions. Before making any voting decision, investors and securityholders are urged to read the Proxy Statement and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transactions as they become available because they will contain important information about the proposed transactions and related matters. Stockholders may obtain a copy of the Proxy Statement and other documents the Company files with the SEC (when they are available) through the website maintained by the SEC at www.sec.gov , as well as on the Investor and News section of Aadi's website at www.aadibio.com . Certain stockholders of Aadi holding approximately 36% of Aadi's outstanding shares, as of the date hereof, including members of its board of directors and related entities, have entered into voting and support agreements in favor of KAKEN Pharmaceutical and Aadi, pursuant to which such stockholders have agreed to vote in favor of the stock purchase transaction with KAKEN Pharmaceutical and the other transactions described above. Participants in the Solicitation Aadi and its respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Aadi in connection with the proposed transactions. Information about Aadi's directors and executive officers is set forth in Aadi's definitive proxy statement filed with the SEC on April 26, 2024 , and in subsequent filings made by Aadi with the SEC. Other information regarding the interests of such individuals, as well as information regarding Aadi's directors and executive officers and other persons who may be deemed participants in the proposed transactions, will be set forth in the Proxy Statement and other relevant materials to be filed with the SEC when they become available. You may obtain free copies of these documents as described in the preceding paragraph. No Offer or Solicitation This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor a solicitation of any vote or approval with respect to the proposed transactions or otherwise, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. The offer and sale of securities of Aadi described above are being made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended, and may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements. Concurrently with the execution of the subscription agreement, the Company and the investors entered into a registration rights agreement pursuant to which the Company has agreed to file, following the closing of the PIPE financing, a registration statement with the SEC registering the resale of the shares of Common Stock and the shares of Common Stock underlying the Pre-Funded Warrants sold in the PIPE financing. About Aadi Bioscience Aadi is a precision oncology company with a vision to make bold choices in applying technology to efficiently deliver improved precision oncology therapies for people living with difficult-to-treat cancers. More information on the Company is available on the Aadi website at www.aadibio.com and connect with us on LinkedIn. Forward-Looking Statements This press release contains certain forward-looking statements regarding the business of Aadi Bioscience that are not a description of historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the Company's current beliefs and expectations and may include, but are not limited to, statements relating to: the timing and completion of the proposed sale of FYARRO to Kaken Pharmaceuticals and the anticipated timing of the closing of the transaction; expectations regarding the timing, closing and completion of the PIPE financing; Aadi's expected cash position at the closing and cash runway of the company following the sale of FYARRO and PIPE financing; the future operations of Aadi; the development and potential benefits of any of Aadi's product candidates, including the preclinical ADC assets proposed to be licensed from WuXi; anticipated preclinical and clinical development activities and related timelines, including the expected timing for announcement of data and other preclinical and clinical results and potential submission of IND filings for one or more product candidates; and other statements that are not historical fact. Actual results could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks associated with (i) the risk that the conditions to the closing of the proposed sale of FYARRO or the PIPE financing are not satisfied, including the failure to timely obtain stockholder approval for the transactions, if at all; (ii) uncertainties as to the timing of the consummation of the proposed transactions and the ability of each of Kaken and Aadi to consummate the proposed sale of FYARRO; (iii) risks related to Aadi's ability to manage its operating expenses and its expenses associated with the proposed transactions pending the closing; (iv) risks related to the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the proposed transactions; (v) unexpected costs, charges or expenses resulting from the transactions; (vii) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed sale of FYARRO or the proposed PIPE financing; (vii) the uncertainties associated with Aadi's product candidates, as well as risks associated with the preclinical and clinical development and regulatory approval of product candidates, including potential delays in the completion of preclinical studies and clinical trials; (viii) risks related to the inability of Aadi to obtain sufficient additional capital to continue to advance these product candidates; (ix) uncertainties in obtaining successful preclinical and clinical results for product candidates and unexpected costs that may result therefrom; (x) risks related to the failure to realize any value from product candidates being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; and (xi) risks associated with the possible failure to realize certain anticipated benefits of the proposed sale of FYARRO or the proposed PIPE financing, including with respect to future financial and operating results. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 , including under the caption "Item 1A. Risk Factors," and in Aadi's subsequent Quarterly Reports on Form 10-Q, and elsewhere in Aadi's reports and other documents that Aadi has filed, or will file, with the SEC from time to time and available at www.sec.gov . All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Aadi undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This cautionary statement is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Contact: IR@aadibio.com View original content to download multimedia: https://www.prnewswire.com/news-releases/aadi-bioscience-transforms-with-in-licensing-of-novel-adc-portfolio-100-million-sale-of-fyarro-and-100-million-pipe-financing-302336743.html SOURCE Aadi Bioscience
Blundering politicos!Philadelphia's Joel Embiid scored 31 points and pulled down 12 rebounds in his return after missing seven games to spark the 76ers on Sunday in a 108-100 NBA victory at Chicago. Embiid had been sidelined by a left knee injury and personal reasons since a November 20 loss to Memphis, the Sixers going 4-3 in his absence. The 30-year-old Cameroonian-born big man, who wore a left knee brace, also added four assists and two blocked shots in 33 minutes in only his fifth game of the season. "He caught fire there," 76ers coach Nick Nurse said of Embiid. "Certainly he gave us a lot of confidence." Philadelphia guard Tyrese Maxey contributed his first career NBA triple-double with 25 points and career highs of 14 assists and 11 rebounds. "It was good," Maxey said. "The offense flowed really well. Pick and roll was really good. I was able to get everybody involved, get Joel going and get myself going too." "He turned on the jets and got to the rim at some pretty opportune times," Nurse said of Maxey. Embiid was a welcome court presence for the 76ers. "He creates so much space for us on the floor, gets the attention," said Maxey. "I didn't see one pick and roll double team for the first time in a long time." Zach LaVine led the Bulls with 30 points. At New York, Milwaukee's Giannis Antetokounmpo scored 34 points and grabbed 11 rebounds to lead the Bucks over the Brooklyn Nets 118-113. Damian Lillard added 15 points and 11 assists while reserve Bobby Portis contributed 23 points and Gary Trent Jr. scored 20 off the Milwaukee bench. Germany's Dennis Schroder led the Nets with 34 points. js/mlm
PHILADELPHIA (AP) — Jalen Hurts may sit out a potential NFC East clincher against Dallas because of the lingering effects of a concussion . The Eagles could also just rest Hurts to play it safe -- even if he’s medically cleared ahead of Sunday’s game -- and protect their franchise QB from additional injury over the final two games. Eagles coach Nick Sirianni kept quiet this week on which QB will start Sunday, in large part, of course, because of the head injury suffered by Hurts in last week’s loss to Washington that forced him into the concussion protocol . The issue was complicated by backup Kenny Pickett’s rib injury suffered in relief of Hurts in his first real game competition in nearly a year. Tanner McKee, the third-string QB, could move into a backup role — or maybe even get the start against the Cowboys. Philadelphia's starting quarterback situation has surged past Saquon Barkley's chase at Eric Dickerson's season rushing record as the most intriguing talking point in the final two games. The Eagles (12-3) appear certain to win the division title — they're two games ahead of Washington (10-5) — and a No. 2 seed in the conference no matter the quarterback headed into the playoffs. Even with an unsettled QB spot, the Eagles are are still 71⁄2-point home favorites to beat division rival Dallas, per BetMGM Sportsbook. Sirianni appreciated that quarterback depth has been a strength for the Eagles. “We feel good about that room,” he said. So why risk Hurts against the Cowboys? There's little reason to make Hurts play only a week after absorbing a pair of blows to the head and the extra week off — maybe two if the finale against the Giants is truly meaningless — could add to his recovery time ahead of a home playoff game. The Eagles were burned in a similar situation last season when Hurts and star wide receiver A.J. Brown were both injured in the final game against the Giants with little at stake. With both players hampered by unnecessary injuries, the Eagles were dumped the next week by Tampa Bay in the NFC wild-card playoff game. The Eagles have options if Hurts is inactive. Pickett was 14 of 24 for 143 yards in relief, throwing a touchdown pass to Brown and an interception. Pickett, a first-round pick out of Pitt in 2022, went 14-10 as a starter for the Steelers before he was traded to the Eagles in the offseason. McKee was the Eagles’ 2023 sixth-round pick out of Stanford. The 6-foot-6, 231-pound quarterback has yet to take a snap in a regular-season game. He's mostly used in practice on the scout team or in developmental periods — at best, he'll stay late after practice to get some reps in with the top receivers. “Every week, every opportunity, it's knowing it could be my shot, my chance,” McKee said. He could finally get that shot against Dallas. With the Cowboys out of playoff contention, the questions persist for coach Mike McCarthy about bypassing Cooper Rush for a look at Trey Lance before both QBs hit free agency. McCarthy’s answer hasn’t wavered: Rush gives Dallas the best chance to win. Rush is 4-3 since Dak Prescott’s season-ending hamstring tear after going 5-1 over two previous stints as an injury replacement. That’s 9-4 total. Half the losses came in both of Rush’s starts against Eagles – the last of five games filling in during the 2022 season and the first game this season. “The mindset is to win,” McCarthy said. “We’re going to Philadelphia to win the game.” Barkley leads the NFL with 1,838 yards rushing for the season through 15 games. He still needs two big outings in the final games of the season against Dallas and the New York Giants to top Dickerson and his 2,105 yards for the Los Angeles Rams in 1984. Barkley is 268 yards away from passing Dickerson for the season mark and 162 shy from becoming the ninth player in NFL history with 2,000 yards rushing in a season. He ran for only 66 yards in the first game this season against Dallas. Dallas ranks 28th in the NFL in rushing defense, surrendering 135.9 yards per contest. Philadelphia, behind Barkley’s stellar play, tops the league at 187.9 yards per game on the ground. The Eagles have already have set a team record for yards rushing in a season with 2,818, and they are within four rushing touchdowns of tying the club’s single-season mark of 32, set in 2022. Barkley needs four more rushing touchdowns to tie LeSean McCoy’s Eagles record, set in 2011 and just 33 yards from scrimmage to break McCoy’s mark of 2,146 set in 2013. Star Dallas edge rusher Micah Parsons needs half a sack to reach double digits in each of his first four seasons despite missing four games with a high ankle sprain, the first injury absence of his career. The 2021 AP Defensive Rookie of the Year would be the fifth player to reach 10 sacks in each of his first four seasons. The other four — Claude Humphrey, Reggie White, Derrick Thomas and Dwight Freeney - are in the Pro Football Hall of Fame. AP Pro Football Writer Schuyler Dixon contributed from Arlington, Texas. AP NFL: https://apnews.com/hub/nfl
Surf Air Mobility Appoints David Anderman to Board of Directors
Townsville Don't miss out on the headlines from Townsville. Followed categories will be added to My News. The month of May began with headlines focused on then Townsville Mayor Troy Thompson and ended with him as he continued to cling to his job despite widespread disdain for the alleged lies about his background during local-government elections. Despite the stain on Townsville’s reputation, a tenacious Thompson’s tenuous grasp on power held by the end of the month, even after then Premiere Steven Miles and the 10 sitting councillors called on him to do the right thing and resign following a calamitous media interview. While the Thompson train wreck provided an unwelcome political sideshow, a number of other pressing issues also made headlines. May 2 Townsville DV Toll at Crisis Point Police on the front-line of Townsville’s domestic violence crisis are facing unprecedented challenges , responding to as many as 50 call-outs a day and they anticipate these numbers will only surge. The Townsville Domestic, Family Violence and Vulnerable Persons Unit say police respond to between 35-50 DV-related call outs every day and anticipate those numbers to rise. Senior Sergeant Adam Golding, Sergeant Elise Feltham and Townsville District Officer Acting Chief Superintendent Tom Armitt, launch Domestic and Family Violence Prevention Month. Picture: Shae Beplate. Third time unlucky ... again Mayor Troy Thompson attempted three motions to gain up to three political advisers, which were denied each time because not enough councillors supported the decision. Councillors also identified their preferred option to act as a chief executive officer known as ‘Candidate Z’ after almost two hours in confidential business. May 3 Thugs steal car from wheelchair-bound mum A woman left wheelchair-bound after being struck by a stolen car has been dealt another devastating blow after her modified vehicle was recently stolen by shameless thieves who openly mocked her . Light in the darkness A young Townsville advocate has opened up about her own experiences with sexual assault as she uses her platform to boost awareness and support for survivors to create discussion on how Australians can create safer spaces. Evie Clayton is an advocate for sexual assault and domestic and family violence survivors. Picture: Shae Beplate. May 4 Bonza demise plane awful North-West Queensland community leaders have been left gutted by the collapse of Bonza airline, with residents now forced to fork out up to 10 times more for flights to see family, friends and for specialist medical appointments. May 8 Green light for mine A $300m phosphate mine in the North West has received a green light, with 445 jobs created as part of the project. The state government has granted mining leases to the Paradise South phosphate mine, about 130km northwest of Mount Isa near the Lady Loretta zinc mine, with plans in place for company North West Phosphate to use local services as part of the project. The Burdekin Rum team at ARDO Rooftop: Kelly Shimota, Tim Lamb, Raelene Bates, Warren Tink, Adrian Hogan, Jason Chan, Olivia McCormick, Prue Yeung, Vicki Johnson and Anthony and Sophie Duggan. Picture: Doug Simpson Media NQ distillery in spirited win A North Queensland distillery is continuing to collect accolades for its range of rums. Burdekin Rum’s Premium Aged Rum has won Best of Category for its bottled and blended pot Still Rum and Best of Class f or its bottled and blended Cane Spirit at the American Distilling Institute International Spirits Competition 2024. May 11 Danger to our kids Social media has been labelled a public health risk with children and young people exposed to damaging images and content they don’t have the developmental maturity to cope with. Acting Chief Health Officer Associate Professor Catherine McDougall told the Townsville Bulletin’s Future Townsville event that social media access for children was causing distress for young people, with it leading to a rise in hospital admissions. Insulted MPs in fight for Bruce North Queensland MPs are “insulted and infuriated” after the Labor government promised $467m for Bruce Highway works in marginal electorates, with one saying a “big picture plan” is needed. LNP MPs Phillip Thompson and Andrew Willcox have come out swinging after the pre-budget announcement, which will fund works in the Far North and South East. May 14 Department of Environment, Science and Innovation Wildlife Officers remove a saltwater crocodile, also known as an estuarine crocodile, measuring at least four metres in length at Port Hinchinbrook in Cardwell. Picture: Cameron Bates Rogue croc caught at Port Hinchinbrook A monster saltwater crocodile believed to be responsible for an attack on a human and death of at least one pet dog has been captured in spectacular fashion at a North Queensland marina. The saltie, also known as an estuarine crocodile, measuring at least four metres in length was caught in a large metal trap placed by the Department of Environment, Science and Innovation at Port Hinchinbrook in Cardwell Waterfront, housing top budget list An upgraded waterfront with the Great Barrier Reef education precinct, a fair chunk of Bruce Highway funding, housing investment and workforce shortage assistance are leading the ticket of North Queensland budget priorities as the nation is poised to hear what projects will get the green light or further funding. Townsville Enterprise has released its priorities for the budget , which includes $100m worth of investment into the GBR education precinct, which would include a new aquarium. May 15 Townsville Bulletin front page, May 15, 2024. Picture: Supplied We deserve better North Queensland’s leaders have come out swinging after last night’s Federal Budget ‘snubbed’ the region, including t he absence of any mone y to rebuild Townsville’s Reef HQ aquarium. Crime far from kid’s play A young Mackay family who moved to Townsville to seek medical treatment for their darling baby girl has received a harrowing introduction to the scourge of local youth crime. Ashleigh Connell, a married mum with 21⁄2-year-old twins Noah and Gracie, said she was prepping breakfast when she noticed “an internal door to the garage was open”. “As I walked outside and notice the side gate open I peered around the corner and my heart fell to the floor,” she said. “My driveway was empty and my new car was gone.” May 16 Robert Malayta, 18, drowned in the Ross River trying to flee police. Teen’s haunting last words as he vanished “Big bro, help” were the last words spoken by a First Nations teenager before he perished in a treacherous river while fleeing from police after reluctantly going for a joy-ride in a stolen car, a pre-inquest into his death has heard . The body of Robert “Robbie” Malayta, 18, was discovered a day later on February 25, 2022, in the Ross River at the Riverway Precinct in Kirwan, Townsville. May 21 Member for Hill Shane Knuth, Member for Hinchinbrook Nick Dametto, Federal Member for Kennedy Bob Katter and KAP Mundingurra candidate Michael Pugh at the Townsville Entertainment Centre. Picture: Evan Morgan MP demands answers as crime cripples As serious youth crime continues to plague Townsville, Hinchinbrook MP Nick Dametto has demanded the Miles Government to provide an urgent update on the progress of its intensive on-country program. Dametto’s call for action comes in the wake of a Townsville boy facing nearly 50 charges related to a series of alleged vehicle, property, and violence offences committed during a three-week rampage. He says it’s already been two months since expressions of interest for the program wrapped up but the public are still waiting for answers. May 23 State’s hotspot of crime Townsville has become the epicentre in the Queensland Police Service’s battle against youth crime, with Taskforce Guardian working overtime to clean up the city’s streets. Since its inception 12 months ago, Taskforce Guardian has launched 13 deployments across the city, surpassing all other police districts across the state . Their efforts within Townsville’s district have resulted in 286 arrests, 871 charges and 129 diversions away from the court system into anti-crime programs. Embattled Townsville mayor Troy Thompson seated next to Councillor Brodie Phillips. Picture: Evan Morgan Mayor not in the SAS Townsville’s mayor has produced his military service number to “put an end” to speculation , however the full contents of his record reveal he did not spend five years in the army or the SAS as he told voters. May 27 Dogs of war Soldiers from across the globe have descended on North Queensland for this year’s Brolga Run Exercise. Troops from Japan, PNG and the US are mucking in together with the locals in pursuit of perfection, but no bond is stronger than the one between our sappers and their canine companions . Australian Army soldier Sapper Flynn Skerke-Irwin and Explosive Detection Dog Ethan from 3rd Combat Engineer Regiment during Exercise Brolga Run 2024 in Townsville Field Training Area, Queensland. May 30 Twist in murder case A Townsville massage parlour owner allegedly killed his wife’s lover in a frenzied stabbing attack when he found out about their affair. Lar Sue, 31, has been charged with murder after allegedly stabbing his wife’s lover above a Thai restaurant on Monday. Sue allegedly confronted his wife and the other man in a Kirwan unit and stabbed him multiple times. May 31 Townsville Bulletin front page, May 31, 2024. Picture: Supplied What a crock Townsville’s embattled mayor is facing fresh allegations of deception, conceding he misled voters about his education, business nous and military career and blaming “100 plus” concussions for his poor memory. Troy Thompson has also apologised to veterans for embellishing his military service in an explosive national television interview in which he disputed lying about his career, saying he “firmly believed” he had given the right information. More Coverage Powders, bars, and banjoes: Our biggest February headlines Cyclones, crime and controversy: Our biggest January headlines Originally published as Townsville Bulletin newspaper headlines for month of May, 2024 Join the conversation Add your comment to this story To join the conversation, please log in. Don't have an account? Register Join the conversation, you are commenting as Logout More related stories News Get job ready: Business offers 17 free training opportunities Staying true to a promise to his grandmother, a Townsville businessman is offering free training to 17 school leavers, unemployed, or under-employed people. Find out more. Read more Townsville ‘We’re always here, always ready’: Christmas Day on the job Essential workers across Townsville spent Christmas Day at work, but they still had plenty of festive spirit. Read about their Christmas. Read more
Kaylene Smikle scored 16 points and made a couple of key baskets down the stretch to help the No. 10 Maryland women’s basketball team hold off George Mason, 66-56, in a matchup of unbeatens Saturday afternoon at the Navy Classic in Annapolis. Maryland (7-0) led by as many as 15 points in the second quarter, but George Mason (6-1) rallied and took the lead late in the third. The Terrapins led by two with just more than three minutes to play when Smikle stole the ball and made a layup while being fouled. The free throw pushed the lead to 58-53, and a putback by Smikle put Maryland up by seven.OSU police probing use of pepper spray in melee
Trump discussed border, trade with Canada's Trudeau after pledging steep tariffsClimate crisis: A plan B needed for wild weather
Continuity Recipe for national success is simple yet powerful: good leaders and long tenures No zero-sum political theatrics, please. No idle shipping containers blocking roads, disrupting lives, and choking the economy, please. Absolutely no disruptive dharnas that paralyse cities. What Pakistanis desperately need are three things: stability, predictability and, above all, continuity of policies. Continuity of policies will provide Pakistan with three critical benefits: attracting investment, fostering sustainable growth, and securing a brighter future for its citizens. Zero-sum political agendas should never be allowed at the expense of national progress. Good leaders – whether uniformed or not – unite people. Bad leaders divide them. Good leaders harness shared values and meaningful connections to foster unity. Bad leaders exploit societal divisions. Bad leaders sow discord. Good leaders – whether uniformed or not – uplift society by healing its wounds; bad leaders exacerbate them. Park Chung-hee, a South Korean politician and former general, served as the country’s third president for 17 years. While his authoritarian rule remains controversial, it was marked by a remarkable continuity of policies that spurred rapid industrialisation and economic growth. Under his leadership, South Korea’s GDP per capita soared from $87 in 1962 to $1,481 in 1980 – an extraordinary 18-fold increase. Lee Teng-hui served as Taiwan’s president for a transformative 12-year period. Lee Teng-hui provided Taiwan with continuity of leadership and continuity of policies. He steered the island's economy away from labour-intensive industries and towards a technologically advanced, high-value manufacturing model. Under his leadership, Taiwan experienced remarkable economic growth, with GDP per capita surging from a modest $6,300 in 1988 to a substantial $15,000 by 2000. Deng Xiaoping's 11-year tenure as China's paramount leader was marked by the 'Reform and Opening Up' policy. Deng, a former military leader, introduced market-oriented economic reforms and opened China to foreign investment. Deng prioritised political stability and social harmony, recognising their importance for economic development. As a result of these reforms, China's GDP per capita soared from $156 in 1978 to $1,400 in just 11 years. Sukarno, a former military officer, led Indonesia for 22 years. While his economic policies were often inconsistent and hindered by political instability, he played a crucial role in laying the foundation for Indonesia's industrialisation and modernisation. Sukarno's ambitious development plans, such as the construction of large-scale infrastructure projects, aimed to modernise the country and improve the lives of its people. Lee Kuan Yew served as Singapore's prime minister for 31 years. Lee had a strong grasp of discipline and strategy. Lee transformed Singapore from a small, impoverished British colony into a global financial hub with one of the highest standards of living in the world. Conclusion: The recipe for national success is simple yet powerful: good leaders and long tenures. Good leaders unite, inspire, and implement forward-looking policies, while long tenures ensure the continuity needed to see those policies bear fruit. Together, they provide the stability and vision essential for lasting progress. In an era of rapid global change, the ability to maintain political stability and economic growth is more crucial than ever. Pakistan, with its immense potential, can realise its destiny if it embraces this simple yet powerful principle: good leaders and long tenures. The writer is a columnist based in Islamabad. He tweets/posts @saleemfarrukh and can be reached at: farrukh15@hotmail.comEx-defense secy: Too early to say Hegseth nomination is dead
Aadi Enters into Exclusive License for Three-Asset ADC Portfolio Developed through a Collaboration between WuXi Biologics and HANGZHOU DAC Aadi Enters Agreement to Sell FYARRO ® and Associated Infrastructure to KAKEN Pharmaceutical for $100M ; Announces PIPE Financing of $100M Cumulative Capital Expected to Fund Operations into Late 2028, Including Anticipated Clinical Data for the ADC Portfolio Co-Founder and Former CEO of ProfoundBio, Baiteng Zhao, Appointed to Aadi Board of Directors Aadi to Hold Webcast and Conference Call on December 20 at 8:00 AM EST LOS ANGELES , Dec. 19, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) today announced it has entered into an exclusive license agreement for development and global commercialization of a three-asset portfolio of preclinical, next-wave antibody-drug conjugates (ADCs), in collaboration with WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), and HANGZHOU DAC BIOTECHNOLOGY CO., LTD. ( HANGZHOU DAC), a global leader in ADC innovation. Per the terms of the license agreement, Aadi is granted exclusive rights to certain patents and know-how pertaining to three preclinical ADC programs leveraging HANGZHOU DAC's CPT113 linker payload technology targeting each of Protein Tyrosine Kinase 7 (PTK7), Mucin-16 (MUC16) and Seizure Related 6 Homolog (SEZ6). Aadi will pay aggregate upfront payments of $44 million for in-licensing such ADC programs. Additionally, Aadi is obligated to pay cumulative development milestone payments of up to $265 million , cumulative commercial milestone payments of up to $540 million and single-digit royalties of sales. To support this transaction, Aadi entered into a subscription agreement with certain qualified institutional buyers and accredited investors for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $100 million , before deducting placement agent fees and other offering expenses. The Company is selling an aggregate of 21,592,000 shares of its common stock ("Common Stock") at a price of $2.40 per share, representing a premium of approximately 3.4% to the closing price on December 19, 2024 on Nasdaq, and pre-funded warrants ("Pre-Funded Warrants") to purchase up to an aggregate of 20,076,500 shares of Common Stock at a purchase price of $2.3999 per Pre-Funded Warrant share. The syndicate was led by Ally Bridge Group, with participation from new investors OrbiMed, Invus, Kalehua Capital and other accredited investors, Tae Han co-founder of ProfoundBio, as well as existing investors, including Avoro Capital, KVP Capital and Acuta Capital Partners. The PIPE financing is expected to close in the first half of 2025, subject to stockholder vote and satisfaction of customary closing conditions. "I'm thrilled to announce our partnership with WuXi Biologics and HANGZHOU DAC to bring forward this thoughtfully selected ADC portfolio. We were deliberate in identifying broadly expressed tumor targets where first-generation ADCs have already shown proof of concept. With our next wave ADC portfolio, we aim to build upon these earlier therapies to deliver improved outcomes for people living with cancer," said David Lennon , PhD, President and CEO of Aadi Bioscience. "The financing underscores the confidence our investors have in both the potential of this portfolio and the strength of Aadi's management team." About the ADC Portfolio Each of the three ADC assets utilizes HANGZHOU DAC's CPT113 ADC platform, which consists of a highly stable yet cleavable linker that delivers a Topoisomerase I (TOPO1) inhibitor payload. The CPT113 platform's linker stability and novel payload has the potential to be highly competitive among the next generation ADC platforms. To effectively leverage the CPT113 platform, Aadi selected tumor targets that are upregulated in high-potential cancer indications and where clinical efficacy has been demonstrated by first-generation ADCs. These assets were discovered through the collaborative efforts of WuXi Biologics and HANGZHOU DAC, utilizing the innovative antibody discovery platform provided by WuXi Biologics and advanced linker-payload technology provided by HANGZHOU DAC. "Leveraging our advanced antibody discovery service, we're glad to enable Aadi to accelerate the discovery of precision therapies targeting some of the most challenging cancers," said Dr. Chris Chen , CEO of WuXi Biologics. "This collaboration underscores our wide recognition as an industry leader in discovery service solutions, and further validates our ability to provide integrated discovery technology platforms for global partners to develop next-generation modalities. We look forward to partnering with Aadi and HANGZHOU DAC to expeditiously move these assets forward into clinical development and benefit patients worldwide." " HANGZHOU DAC's CPT-ADC platform is designed to enable next wave ADC capabilities that surpass first-generation technologies, including two programs already in clinical development in China ," said Dr. Robert Y. Zhao , President and CEO of HANGZHOU DAC Biotechnology. "As a global leader in ADC innovation, we are excited to partner with Aadi and WuXi Biologics to deliver this promising portfolio to patients." Aadi to Sell FYARRO for $100 Million , Cumulative Capital Expected to Fund Operations into Late 2028 In a separate agreement, KAKEN Pharmaceutical Co., Ltd., an R&D driven pharmaceutical company in Japan , has entered into a stock purchase agreement under which KAKEN will acquire Aadi Subsidiary, Inc. and all of its assets, including FYARRO ® (sirolimus protein-bound particles for injectable suspension) (albumin-bound) and associated infrastructure, including the majority of Aadi employees who support the FYARRO ® business. FYARRO is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa), with cumulative revenue of $25.2 million reported over the prior four quarters ended September 30, 2024 . Per the terms of the agreement, Kaken will pay Aadi $100 million in cash at closing, subject to certain adjustments. The transaction is expected to close in the first half of 2025, subject to Aadi stockholder approval and certain closing conditions. Upon the closing of this transaction, KAKEN will also acquire the rights to the Aadi name and trademark. "We are enormously proud of the impact FYARRO has had for people with PEComa, and Kaken's capabilities, coupled with the proven track record of the Aadi team, ensures physicians and patients will continue to have access to this critical treatment," said Lennon. The net proceeds from the PIPE financing and the sale of FYARRO, together with the Company's existing cash, cash equivalents and marketable securities are expected to fund operations into late-2028, including anticipated clinical data readouts for the ADC portfolio. Baiteng Zhao Appointed to the Board of Directors, Brings Significant ADC Expertise Baiteng Zhao, PhD, joins Aadi's board of directors. Zhao co-founded ProfoundBio, a clinical stage next-gen ADC developer, in 2018 and served as the Chairman and CEO of the company until it was acquired by Genmab for $1.8 billion in May 2024 . Prior to ProfoundBio, Dr. Zhao worked at Seagen (now part of Pfizer) for more than eight years and was responsible for the modeling and simulation strategies for the development pipeline and supported preclinical and clinical development of ADC drug candidates. "We are delighted to welcome Baiteng to our Board. His deep expertise and successful track record in ADC development will be instrumental as we tenaciously move this exciting portfolio forward," said Caley Castelein , MD, Chair of the Board of Directors of Aadi Bioscience. "I am thrilled to join the Board at this pivotal moment for Aadi," said Baiteng Zhao, PhD, Board of Directors of Aadi Bioscience and co-founder of ProfoundBio. "PTK7, MUC16 and SEZ6 represent highly promising targets that are commonly overexpressed in cancers with significant unmet therapeutic needs. Coupled with an advanced linker-payload platform that has the potential to enable next-gen ADCs, I believe Aadi is uniquely positioned to make a meaningful impact on patient outcomes. I look forward to collaborating with the leadership team and fellow Board directors to advance these innovative programs and drive transformative progress for patients." Advisors Leerink Partners is serving as financial advisor to Aadi on the sale of FYARRO and the licensing of the ADC portfolio. Jefferies LLC is acting as exclusive placement agent for the PIPE financing. Wilson Sonsini Goodrich & Rosati, P.C. is serving as legal counsel to Aadi. McDermott Will & Emery LLP is serving as legal counsel to Kaken. Cooley LLP is serving as legal counsel to Jefferies LLC. Nomura Securities Co., Ltd. is serving as financial advisor to KAKEN. Conference Call Information The Aadi management team is hosting a conference call and webcast tomorrow, Friday, December 20 th at 8:00 AM EST ( 5:00 AM PST ) to discuss these updates. Participants may access a live webcast of the call and the associated slide presentation on these data through the "Investors & News" page of the Aadi Bioscience website at aadibio.com . To participate via telephone, please register in advance at this link . Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the Company's website for at least 30 days. Additional Information for Stockholders This communication relates to the proposed sale of FYARRO and the proposed PIPE financing and may be deemed to be solicitation material in respect of such transactions. In connection with these proposed transactions, Aadi will file a Proxy Statement with the SEC. This communication is not a substitute for the Proxy Statement or any other documents that Aadi may file with the SEC or send to Aadi stockholders in connection with the proposed transactions. Before making any voting decision, investors and securityholders are urged to read the Proxy Statement and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transactions as they become available because they will contain important information about the proposed transactions and related matters. Stockholders may obtain a copy of the Proxy Statement and other documents the Company files with the SEC (when they are available) through the website maintained by the SEC at www.sec.gov , as well as on the Investor and News section of Aadi's website at www.aadibio.com . Certain stockholders of Aadi holding approximately 36% of Aadi's outstanding shares, as of the date hereof, including members of its board of directors and related entities, have entered into voting and support agreements in favor of KAKEN Pharmaceutical and Aadi, pursuant to which such stockholders have agreed to vote in favor of the stock purchase transaction with KAKEN Pharmaceutical and the other transactions described above. Participants in the Solicitation Aadi and its respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Aadi in connection with the proposed transactions. Information about Aadi's directors and executive officers is set forth in Aadi's definitive proxy statement filed with the SEC on April 26, 2024 , and in subsequent filings made by Aadi with the SEC. Other information regarding the interests of such individuals, as well as information regarding Aadi's directors and executive officers and other persons who may be deemed participants in the proposed transactions, will be set forth in the Proxy Statement and other relevant materials to be filed with the SEC when they become available. You may obtain free copies of these documents as described in the preceding paragraph. No Offer or Solicitation This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor a solicitation of any vote or approval with respect to the proposed transactions or otherwise, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. The offer and sale of securities of Aadi described above are being made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended, and may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements. Concurrently with the execution of the subscription agreement, the Company and the investors entered into a registration rights agreement pursuant to which the Company has agreed to file, following the closing of the PIPE financing, a registration statement with the SEC registering the resale of the shares of Common Stock and the shares of Common Stock underlying the Pre-Funded Warrants sold in the PIPE financing. About Aadi Bioscience Aadi is a precision oncology company with a vision to make bold choices in applying technology to efficiently deliver improved precision oncology therapies for people living with difficult-to-treat cancers. More information on the Company is available on the Aadi website at www.aadibio.com and connect with us on LinkedIn. Forward-Looking Statements This press release contains certain forward-looking statements regarding the business of Aadi Bioscience that are not a description of historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the Company's current beliefs and expectations and may include, but are not limited to, statements relating to: the timing and completion of the proposed sale of FYARRO to Kaken Pharmaceuticals and the anticipated timing of the closing of the transaction; expectations regarding the timing, closing and completion of the PIPE financing; Aadi's expected cash position at the closing and cash runway of the company following the sale of FYARRO and PIPE financing; the future operations of Aadi; the development and potential benefits of any of Aadi's product candidates, including the preclinical ADC assets proposed to be licensed from WuXi; anticipated preclinical and clinical development activities and related timelines, including the expected timing for announcement of data and other preclinical and clinical results and potential submission of IND filings for one or more product candidates; and other statements that are not historical fact. Actual results could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks associated with (i) the risk that the conditions to the closing of the proposed sale of FYARRO or the PIPE financing are not satisfied, including the failure to timely obtain stockholder approval for the transactions, if at all; (ii) uncertainties as to the timing of the consummation of the proposed transactions and the ability of each of Kaken and Aadi to consummate the proposed sale of FYARRO; (iii) risks related to Aadi's ability to manage its operating expenses and its expenses associated with the proposed transactions pending the closing; (iv) risks related to the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the proposed transactions; (v) unexpected costs, charges or expenses resulting from the transactions; (vii) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed sale of FYARRO or the proposed PIPE financing; (vii) the uncertainties associated with Aadi's product candidates, as well as risks associated with the preclinical and clinical development and regulatory approval of product candidates, including potential delays in the completion of preclinical studies and clinical trials; (viii) risks related to the inability of Aadi to obtain sufficient additional capital to continue to advance these product candidates; (ix) uncertainties in obtaining successful preclinical and clinical results for product candidates and unexpected costs that may result therefrom; (x) risks related to the failure to realize any value from product candidates being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; and (xi) risks associated with the possible failure to realize certain anticipated benefits of the proposed sale of FYARRO or the proposed PIPE financing, including with respect to future financial and operating results. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 , including under the caption "Item 1A. Risk Factors," and in Aadi's subsequent Quarterly Reports on Form 10-Q, and elsewhere in Aadi's reports and other documents that Aadi has filed, or will file, with the SEC from time to time and available at www.sec.gov . All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Aadi undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This cautionary statement is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Contact: IR@aadibio.com View original content to download multimedia: https://www.prnewswire.com/news-releases/aadi-bioscience-transforms-with-in-licensing-of-novel-adc-portfolio-100-million-sale-of-fyarro-and-100-million-pipe-financing-302336743.html SOURCE Aadi Bioscience
Blundering politicos!Philadelphia's Joel Embiid scored 31 points and pulled down 12 rebounds in his return after missing seven games to spark the 76ers on Sunday in a 108-100 NBA victory at Chicago. Embiid had been sidelined by a left knee injury and personal reasons since a November 20 loss to Memphis, the Sixers going 4-3 in his absence. The 30-year-old Cameroonian-born big man, who wore a left knee brace, also added four assists and two blocked shots in 33 minutes in only his fifth game of the season. "He caught fire there," 76ers coach Nick Nurse said of Embiid. "Certainly he gave us a lot of confidence." Philadelphia guard Tyrese Maxey contributed his first career NBA triple-double with 25 points and career highs of 14 assists and 11 rebounds. "It was good," Maxey said. "The offense flowed really well. Pick and roll was really good. I was able to get everybody involved, get Joel going and get myself going too." "He turned on the jets and got to the rim at some pretty opportune times," Nurse said of Maxey. Embiid was a welcome court presence for the 76ers. "He creates so much space for us on the floor, gets the attention," said Maxey. "I didn't see one pick and roll double team for the first time in a long time." Zach LaVine led the Bulls with 30 points. At New York, Milwaukee's Giannis Antetokounmpo scored 34 points and grabbed 11 rebounds to lead the Bucks over the Brooklyn Nets 118-113. Damian Lillard added 15 points and 11 assists while reserve Bobby Portis contributed 23 points and Gary Trent Jr. scored 20 off the Milwaukee bench. Germany's Dennis Schroder led the Nets with 34 points. js/mlm
PHILADELPHIA (AP) — Jalen Hurts may sit out a potential NFC East clincher against Dallas because of the lingering effects of a concussion . The Eagles could also just rest Hurts to play it safe -- even if he’s medically cleared ahead of Sunday’s game -- and protect their franchise QB from additional injury over the final two games. Eagles coach Nick Sirianni kept quiet this week on which QB will start Sunday, in large part, of course, because of the head injury suffered by Hurts in last week’s loss to Washington that forced him into the concussion protocol . The issue was complicated by backup Kenny Pickett’s rib injury suffered in relief of Hurts in his first real game competition in nearly a year. Tanner McKee, the third-string QB, could move into a backup role — or maybe even get the start against the Cowboys. Philadelphia's starting quarterback situation has surged past Saquon Barkley's chase at Eric Dickerson's season rushing record as the most intriguing talking point in the final two games. The Eagles (12-3) appear certain to win the division title — they're two games ahead of Washington (10-5) — and a No. 2 seed in the conference no matter the quarterback headed into the playoffs. Even with an unsettled QB spot, the Eagles are are still 71⁄2-point home favorites to beat division rival Dallas, per BetMGM Sportsbook. Sirianni appreciated that quarterback depth has been a strength for the Eagles. “We feel good about that room,” he said. So why risk Hurts against the Cowboys? There's little reason to make Hurts play only a week after absorbing a pair of blows to the head and the extra week off — maybe two if the finale against the Giants is truly meaningless — could add to his recovery time ahead of a home playoff game. The Eagles were burned in a similar situation last season when Hurts and star wide receiver A.J. Brown were both injured in the final game against the Giants with little at stake. With both players hampered by unnecessary injuries, the Eagles were dumped the next week by Tampa Bay in the NFC wild-card playoff game. The Eagles have options if Hurts is inactive. Pickett was 14 of 24 for 143 yards in relief, throwing a touchdown pass to Brown and an interception. Pickett, a first-round pick out of Pitt in 2022, went 14-10 as a starter for the Steelers before he was traded to the Eagles in the offseason. McKee was the Eagles’ 2023 sixth-round pick out of Stanford. The 6-foot-6, 231-pound quarterback has yet to take a snap in a regular-season game. He's mostly used in practice on the scout team or in developmental periods — at best, he'll stay late after practice to get some reps in with the top receivers. “Every week, every opportunity, it's knowing it could be my shot, my chance,” McKee said. He could finally get that shot against Dallas. With the Cowboys out of playoff contention, the questions persist for coach Mike McCarthy about bypassing Cooper Rush for a look at Trey Lance before both QBs hit free agency. McCarthy’s answer hasn’t wavered: Rush gives Dallas the best chance to win. Rush is 4-3 since Dak Prescott’s season-ending hamstring tear after going 5-1 over two previous stints as an injury replacement. That’s 9-4 total. Half the losses came in both of Rush’s starts against Eagles – the last of five games filling in during the 2022 season and the first game this season. “The mindset is to win,” McCarthy said. “We’re going to Philadelphia to win the game.” Barkley leads the NFL with 1,838 yards rushing for the season through 15 games. He still needs two big outings in the final games of the season against Dallas and the New York Giants to top Dickerson and his 2,105 yards for the Los Angeles Rams in 1984. Barkley is 268 yards away from passing Dickerson for the season mark and 162 shy from becoming the ninth player in NFL history with 2,000 yards rushing in a season. He ran for only 66 yards in the first game this season against Dallas. Dallas ranks 28th in the NFL in rushing defense, surrendering 135.9 yards per contest. Philadelphia, behind Barkley’s stellar play, tops the league at 187.9 yards per game on the ground. The Eagles have already have set a team record for yards rushing in a season with 2,818, and they are within four rushing touchdowns of tying the club’s single-season mark of 32, set in 2022. Barkley needs four more rushing touchdowns to tie LeSean McCoy’s Eagles record, set in 2011 and just 33 yards from scrimmage to break McCoy’s mark of 2,146 set in 2013. Star Dallas edge rusher Micah Parsons needs half a sack to reach double digits in each of his first four seasons despite missing four games with a high ankle sprain, the first injury absence of his career. The 2021 AP Defensive Rookie of the Year would be the fifth player to reach 10 sacks in each of his first four seasons. The other four — Claude Humphrey, Reggie White, Derrick Thomas and Dwight Freeney - are in the Pro Football Hall of Fame. AP Pro Football Writer Schuyler Dixon contributed from Arlington, Texas. AP NFL: https://apnews.com/hub/nfl
Surf Air Mobility Appoints David Anderman to Board of Directors